Activation of NF-κB by the intracellular expression of NF-κB-inducing kinase acts as a powerful vaccine adjuvant
- 26 September 2006
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (39), 14459-14464
- https://doi.org/10.1073/pnas.0603493103
Abstract
There is a pressing need for adjuvants that will enhance the effectiveness of genetic vaccines. This is particularly important in cancer and infectious disease such as HIV and malaria for which successful vaccines are desperately needed. Here, we describe an approach to enhance immunogenicity that involves the activation of NF-κB by the transgenic expression of an intracellular signaling molecule, NF-κB-inducing kinase (NIK). In vitro, NIK increases dendritic cell antigen presentation in allogeneic and antigen-specific T cell proliferation assays by potently activating NF-κB and consequently up-regulating the expression of cytokines (TNF-α, IL-6, IL-12, IL-15, and IL-18), chemokines [IL-8, RANTES (regulated on activation, normal T cell expressed and secreted), macrophage inflammatory protein-1α, monocyte chemoattractant protein-1, and monocyte chemoattractant protein-3], MHC antigen-presenting molecules (class I and II), and costimulatory molecules (CD80 and CD86). In vivo, NIK enhances immune responses against a vector-encoded antigen and shifts them toward a T helper 1 immune response with increased IgG2a levels, T cell proliferation, IFN-γ production, and cytotoxic T lymphocyte responses more potently than complete Freund's adjuvant, a very efficacious T helper 1-inducing adjuvant. These findings define NIK, and possibly other inducers of NF-κB activation, as a potent adjuvant strategy that offers great potential for genetic vaccine development.Keywords
This publication has 52 references indexed in Scilit:
- Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategiesVaccine, 2005
- Distinct pathways of LPS-induced NF-κB activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAPBlood, 2004
- Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primatesNature, 2003
- Heterogeneous requirement of IκB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: Implications for therapyArthritis & Rheumatism, 2003
- RelB Cellular Regulation and Transcriptional Activity Are Regulated by p100Journal of Biological Chemistry, 2002
- Effective antigen presentation by dendritic cells is NF-κB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokinesInternational Immunology, 2001
- Immune response to green fluorescent protein: implications for gene therapyGene Therapy, 1999
- Dendritic Cell Survival and Maturation Are Regulated by Different Signaling PathwaysThe Journal of Experimental Medicine, 1998
- Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.The Journal of Experimental Medicine, 1995
- Antigen-specific interaction between T and B cellsNature, 1985